Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination with Rituximab in subjects with Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma. 40 Participant will be screened for 20 subjects enrollment.

Trial Details

NCT ID
NCT07125872
Phase
PHASE2
Sponsor
ImmunityBio, Inc.
Status
RECRUITING
Cancer Type
T-Cell Lymphoma Lymphoma
Interventions
  • CD19 t-haNK- IV Administration
Locations (sample)
  • Johannesburg, South Africa|-26.20227,28.04363
  • Pretoria, South Africa|-25.74486,28.18783

Key Eligibility Criteria

  • 1- Age\>18 years old 2- Able to understand and provide a signed informed consent that fulfills the relevant Human Research Ethics Committee( HRECC)…
  • Have completed ≥2 lines of cytotoxic chemotherapy.
  • Have received rituximab or another anti-CD20 antibody.
  • Have measurable disease by Lugano classification documented within 8 weeks of the time of consent, defined as nodal lesions \>15 mm in the long axi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find T-Cell Lymphoma Lymphoma Trials on Trialify →